In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- The CDMO industry in the wake of COVID-19
- Near-term outlook
- Medium-term could be challenging
- Longer-term implications